Merck submits app to EMA for metastatic sarcoma drug ridaforolimus
This article was originally published in Scrip
Executive Summary
Shares of Ariad climbed as high as 6.7%, or 80 cents, on 1 August on the news that the firm's partner Merck submitted a marketing authorization application (MAA) on 29 July for its investigational mTOR inhibitor ridaforolimus to the European Medicines Agency (EMA) seeking approval of the drug as a treatment for patients with metastatic sarcomas.